About BridgeCross Bio
A More Nuanced Conversation About China and Biotech
Our goal at BridgeCross Bio is to provide audiences with an accurate, contextual understanding of China's biotech and medtech landscape. We are neither pro- nor anti-China. We do not aim to hype, nor to vilify. We believe that good reporting, like good science, should follow the data.
The BridgeCross Map is an interactive directory of Chinese biotech companies across four sectors: Sequencing Technology, DNA Synthesis, Liquid Biopsy Oncology, and AI Drug Discovery — plus the venture capital firms backing them.
What you can expect from BridgeCross
- Independent analysis: Editorially independent, no government or political funding.
- On-the-ground insight: Contributors have worked and built careers within China's science ecosystem.
- Global relevance: China's biotech policies and companies will shape scientific and commercial decisions globally in the decade ahead.
The Team
Who We Are
Matt Marlowe
Director & Founder
Matt Marlowe is a marketing strategist specialised in helping life science and biotech teams turn complex science into clear, commercial narratives. With deep experience in genomics and molecular diagnostics, Matt partners with founders and product leaders to position offerings, accelerate adoption, and drive measurable market traction.
LinkedIn →
Michelle (Qian) Mao
Consultant
Michelle Mao is a seasoned life sciences and genomics expert with over 15 years of experience in molecular diagnostics, IVD, and global healthcare market expansion. Her expertise covers the full spectrum of product and partner lifecycle management — from R&D alignment and regulatory strategy to channel enablement, KOL engagement, and post-market support.